Avanos Medical Inc. (AVNS) stock plummeted more than 10% in the pre-market trading session on Wednesday, following the release of the company's disappointing fourth-quarter results and underwhelming guidance for the full year.
The medical technology company reported a staggering net loss of $397.3 million for the fourth quarter, with an operating loss of $418.5 million and an EBITDA loss of $407.6 million. Despite generating $179.6 million in sales, Avanos Medical's gross profit stood at a mere $98 million, reflecting the company's significant operational challenges.
Adding to the concerns, Avanos Medical provided a lackluster earnings guidance for the full year, projecting an adjusted EPS range of $1.05 to $1.25, significantly lower than market expectations. The company's weak outlook further exacerbated investors' concerns about its future prospects, contributing to the pre-market sell-off.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.